Breakthrough in Cancer Gene Therapy: Researchers Develop Tropism-Retargeted Herpes Simplex Virus

Strategic Insights -

Research conducted by a team at the University of Bologna in Italy has led to a significant advancement in cancer gene therapy. The team, led by Andrea Vannini, has created a novel approach using tropism-retargeted herpes simplex virus (ReHVs) to elicit an immune response against cancer cells without the need for direct tumor treatment. This innovative technique has the potential to revolutionize the treatment of hard-to-reach, unresectable, or metastatic lesions.

Key Takeaways:

  • The research team at the University of Bologna has developed a tropism-retargeted herpes simplex virus (ReHVs) that specifically targets tumor-associated antigens (TAAs), making it an effective tool for cancer immunotherapy.
  • The ReHVs-based immunotherapeutic platform (Re-IP) was shown to prime anticancer T cells, which infiltrated distant untreated tumors and inhibited their growth, even in the presence of prior antiviral immunity.
  • Re-IP exhibited an adjuvant effect, enhancing the immunogenicity of cancer cells without direct tumor treatment, and remained effective in mice with prior immunity to herpes simplex virus (HSV).
  • In humans, this approach might be applied to elicit anticancer T-cell responses against hard-to-reach, unresectable, or metastatic lesions and to enhance immune cell activation and expansion in adoptive therapies.

Statistics:

  • The research study was published in the Journal for ImmunoTherapy of Cancer, Volume 13, Issue 7, 2025.
  • The study was funded by the European Research Council and Nextgenerationeu.
  • The research team included Andrea Vannini, Federico Parenti, Cristina Forghieri, Elisabetta Romagnoli, Daniela Massaro, Anna Zaghini, Gabriella Campadelli-Fiume, and Tatiana Gianni.
  • The therapeutic approach was effective in mice, with a significant reduction in tumor growth.

Sources:

  • Journal for ImmunoTherapy of Cancer. (2025). Gnostic and agnostic immunotherapy by tropism-retargeted herpes simplex virus without direct tumor treatment. Volume 13, Issue 7, 2025.
  • Gnostic and agnostic immunotherapy by tropism-retargeted herpes simplex virus without direct tumor treatment. (Journal for ImmunoTherapy of Cancer - http://www.immunotherapyofcancer.org/).
  • BMJ Publishing Group. (2025). Journal for ImmunoTherapy of Cancer.
  • https://doi-org.sdpl.idm.oclc.org/10.1136/jitc-2025-011812.